Flumethasone
Solid powder
Others
Flumethasone is a synthetic glucocorticoid that is widely used in medical, environmental, and industrial research. It is a potent anti-inflammatory and immunosuppressive agent that has been used in the treatment of various inflammatory and autoimmune diseases. Flumethasone is also used in environmental research to study its effects on ecosystems and pollution management. In industrial research, it is used in manufacturing processes to improve product quality and efficiency. This paper aims to provide a comprehensive review of flumethasone, including its method of synthesis or extraction, chemical structure and biological activity, biological effects, applications, and future perspectives and challenges.
410.5 g/mol
410.5 g/mol
Formulation:
410.5 g/mol
Source:
Usage:
Flumethasone
The product is for non-human research only. Not for therapeutic or veterinary use.
Catalog Number: BT-268298
CAS Number: 2135-17-3
Molecular Formula: C22H28F2O5
Molecular Weight: 410.5 g/mol
| CAS Number | 2135-17-3 |
|---|---|
| Product Name | Flumethasone |
| Molecular Formula | C22H28F2O5 |
| Molecular Weight | 410.5 g/mol |
| Appearance | Solid powder |
| InChI | InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13?,14?,16+,17+,19+,20+,21+,22+/m1/s1 |
| InChI Key | WXURHACBFYSXBI-DRBBXQFKSA-N |
| Isomeric SMILES | C[C@@H]1CC2C3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)F |
| IUPAC Name | (6S,9R,10S,11S,13S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one |
| Canonical SMILES | CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C)F |
| Description | Flumethasone is a synthetic glucocorticoid that is widely used in medical, environmental, and industrial research. It is a potent anti-inflammatory and immunosuppressive agent that has been used in the treatment of various inflammatory and autoimmune diseases. Flumethasone is also used in environmental research to study its effects on ecosystems and pollution management. In industrial research, it is used in manufacturing processes to improve product quality and efficiency. This paper aims to provide a comprehensive review of flumethasone, including its method of synthesis or extraction, chemical structure and biological activity, biological effects, applications, and future perspectives and challenges. |
| Method of Synthesis or Extraction | Flumethasone is synthesized by the reaction of 6α-fluoro-16α-methylprednisolone with acetic anhydride in the presence of a catalyst. The yield of this method is around 70%, and the process is relatively efficient. However, the use of acetic anhydride as a reagent can be hazardous to the environment and human health. Alternative methods of synthesis include the reaction of 6α-fluoro-16α-methylprednisolone with trifluoroacetic anhydride or trifluoroacetic acid. These methods have a higher yield of around 90%, but they also have environmental and safety considerations. |
| Chemical Structure and Biological Activity | Flumethasone has a chemical structure similar to other glucocorticoids, with a 21-carbon skeleton and a ketone group at position 3. It binds to the glucocorticoid receptor and regulates gene expression, leading to its anti-inflammatory and immunosuppressive effects. Flumethasone has a high potency and a long duration of action, making it an effective treatment for various inflammatory and autoimmune diseases. |
| Biological Effects | Flumethasone has a wide range of biological effects on cell function and signal transduction. It inhibits the production of pro-inflammatory cytokines and chemokines, reduces the migration of immune cells to sites of inflammation, and suppresses the activation of T cells and B cells. Flumethasone also has potential therapeutic and toxic effects, depending on the dose and duration of treatment. It can cause side effects such as osteoporosis, diabetes, and adrenal suppression. |
| Applications | In medical research, flumethasone has been used in drug development and clinical trials for various inflammatory and autoimmune diseases, such as rheumatoid arthritis, asthma, and inflammatory bowel disease. It has shown promising results in reducing inflammation and improving symptoms in these diseases. However, its potential side effects need to be carefully monitored. In environmental research, flumethasone has been studied for its effects on ecosystems and pollution management. It has been found to have toxic effects on aquatic organisms and can accumulate in the environment. In industrial research, flumethasone is used in manufacturing processes to improve product quality and efficiency. Health and safety considerations need to be taken into account when handling flumethasone in industrial settings. |
| Future Perspectives and Challenges | The use of flumethasone in medical, environmental, and industrial research is likely to continue in the future. However, there are current limitations in its use and study, such as its potential side effects and environmental impact. Possible solutions and improvements include the development of safer and more effective glucocorticoids, the use of alternative methods of synthesis or extraction, and the implementation of sustainable practices in industrial settings. Future trends and prospects in the application of flumethasone in scientific research will depend on these developments and the continued evaluation of its benefits and risks. Conclusion: Flumethasone is a synthetic glucocorticoid that has been widely used in medical, environmental, and industrial research. Its method of synthesis or extraction, chemical structure and biological activity, biological effects, applications, and future perspectives and challenges have been reviewed in this paper. Flumethasone has shown promising results in the treatment of various inflammatory and autoimmune diseases, but its potential side effects and environmental impact need to be carefully monitored. The development of safer and more effective glucocorticoids and the implementation of sustainable practices in industrial settings are important for the future application of flumethasone in scientific research. |
| Shelf Life | >2 years if stored properly |
| SMILES | CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C)F |
| Solubility | Soluble in DMSO. |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Synonyms | 69difluoro1117 21trihydroxy16methylpregna14diene320dione 1721diacetate |
| Reference | 1: Maccaroni E, Giovenzana GB, Palmisano G, Botta D, Volante P, Masciocchi N. Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11. Epub 2008 Oct 18. PubMed PMID: 19013475. 2: Bäumer W, Seegers U, Braun M, Tschernig T, Kietzmann M. TARC and RANTES, but not CTACK, are induced in two models of allergic contact dermatitis. Effects of cilomilast and diflorasone diacetate on T-cell-attracting chemokines. Br J Dermatol. 2004 Oct;151(4):823-30. PubMed PMID: 15491423. 3: Mandrea E. Topical diflorasone ointment for treatment of recalcitrant, excessive granulation tissue. Dermatol Surg. 1998 Dec;24(12):1409-10. PubMed PMID: 9865213. 4: Krueger GG, O'Reilly MA, Weidner M, Dromgoole SH, Killey FP. Comparative efficacy of once-daily flurandrenolide tape versus twice-daily diflorasone diacetate ointment in the treatment of psoriasis. J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):186-90. PubMed PMID: 9486672. 5: Shupack JL, Jondreau L, Kenny C, Stiller MJ. Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis. Dermatology. 1993;186(2):129-32. PubMed PMID: 8428041. 6: Jegasothy BV. Clobetasol propionate ointment 0.05% versus diflorasone diacetate ointment 0.05% in moderate to severe psoriasis. Int J Dermatol. 1990 Dec;29(10):729-30. PubMed PMID: 2269571. 7: Rozman TA. [Topical treatment of glucocorticoid-sensitive dermatoses with diflorasone diacetate]. Z Hautkr. 1986 Mar 1;61(5):294, 297-304. German. PubMed PMID: 3962411. 8: Spencer SA, Fenske NA, Bookbinder SA, Vasey FB. Diflorasone diacetate ointment 0.05 percent in conjunction with UVB and tar in a modified outpatient Goeckerman regimen. Cutis. 1985 Aug;36(2):169-72. PubMed PMID: 4028832. 9: Shaw MC, Vanderwielen AJ. Liquid chromatographic assay for diflorasone diacetate in cream and ointment formulations. J Pharm Sci. 1984 Nov;73(11):1606-8. PubMed PMID: 6520764. 10: Schneider WD. [Efficacy and safety of topical 0.05% diflorasone diacetate (florone) cream/ointment in patients with acute/chronic dermatitis]. Z Hautkr. 1984 Oct 1;59(19):1312, 1319-22. German. PubMed PMID: 6391003. |
| PubChem Compound | Flumethasone |
| Last Modified | May 30 2023 |